ClinConnect ClinConnect Logo
Search / Trial NCT06697470

Muscle and Subcutaneous Tissue Variation by Ultrasound and Impedance Linked to Fluid Balance in ICU Patients

Launched by DR F DUPREZ · Nov 17, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Muscle Thickness Subcutaneous Tissue Ultrasound Bioelectrical Impedance Analysis Bia Fluid Balance Icu (Intensive Care Unit) Muscle Strength Mrc Sum Score Grip Strength Edema Assessment Critical Care Skeletal Muscle Hydration Status Muscle Echogenicity Icu Acquired Weakness Fluid Compartments Extracellular Water Intracellular Water Body Composition Bedside Ultrasound Fluid Management Early Mobilization Volume Overload Tissue Edema Body Water Compartments Length Of Icu Stay Muscle Quality

ClinConnect Summary

This clinical trial is studying how changes in muscle thickness and tissue under the skin relate to fluid balance in critically ill patients in the intensive care unit (ICU). When patients are in the ICU, they often experience muscle loss and swelling due to various factors, including inflammation and receiving large amounts of fluids. Researchers will use ultrasound to measure muscle thickness and a technique called bioelectrical impedance analysis (BIA) to assess fluid levels in the body. The goal is to see how fluid management affects muscle health and strength, which can help improve recovery strategies for patients in the ICU.

To participate in this study, patients need to be adults over 18 years old and admitted to the ICU at Epicura Hornu Hospital during the specified dates. They must also provide consent to join the study. Participants can expect daily assessments of their fluid balance, muscle measurements, and strength tests before they leave the ICU. This research aims to improve our understanding of how fluid levels impact muscle health in critically ill patients, ultimately leading to better care and rehabilitation approaches.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults aged over 18 years.
  • Patients present and admitted to the ICU at Epicura Hornu Hospital between October 14, 2024, and November 15, 2024 (to be updated).
  • Informed consent to participate in the study has been signed by the patient or their legal representative.
  • Exclusion Criteria :
  • Patients in post-operative or other surveillance with an expected ICU stay of less than 48 hours.
  • Patients for whom a decision to withdraw therapy has been made prior to inclusion.
  • Presence of skin conditions (e.g., wounds or ulcers) that hinder ultrasound measurements or the application of skin electrodes.
  • Pregnancy.
  • Presence of an implanted pacemaker or defibrillator.

About Dr F Duprez

Dr. F. Duprez is a distinguished clinical trial sponsor renowned for advancing medical research and innovation. With a commitment to enhancing patient care through rigorous scientific investigation, Dr. Duprez leads a team of experts dedicated to the design, implementation, and management of clinical trials across various therapeutic areas. By prioritizing ethical standards and participant safety, the organization fosters collaborative partnerships with healthcare professionals and research institutions, aiming to translate findings into meaningful health solutions. Dr. Duprez's focus on evidence-based practices ensures that each trial contributes valuable insights to the medical community and ultimately improves patient outcomes.

Locations

Boussu, Hainaut, Belgium

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported